REGENXBIO announces participation in investor conferences this month.
- REGENXBIO to attend various investor conferences.
- Discussions will focus on the company's business strategy.
- Opportunity for investors to learn about REGENXBIO's developments.
REGENXBIO, a biotechnology company known for its work in gene therapy, has announced its participation in two upcoming investor conferences this September. The company aims to engage with investors and provide insights into its business strategies and product pipeline. These presentations represent an opportunity for stakeholders to gain a deeper understanding of REGENXBIO's innovations in the field of gene therapy.
The first event will be the H.C. Wainwright 25th Annual Global Investment Conference, which is scheduled for September 11-13, 2023, in New York. Following that, REGENXBIO will take part in the Cantor Fitzgerald Global Healthcare Conference on September 27, 2023. At both conferences, the company will discuss its advancements and strategic direction within the biotechnology sector.
REGENXBIO’s participation in these investor conferences underscores its commitment to transparent investor relations. The presentations will shed light on the company's progress and future plans, as it continues to explore new possibilities in gene therapy. These engagements provide valuable forums for interaction between the company and the investment community.
